Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-5 of 5

Sort by

Sort Order Select

Journal Articles

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Blood (2024) 144 (1): 35–45.

https://doi.org/10.1182/blood.2023022658

Published: 2024

Includes: Supplemental data

Journal Articles

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

David C. Dale, Frank Caleb Firkin, Audrey Anna Bolyard, Weihua Tang, Honghua Jiang, Richard MacLeod, Diego Cadavid, Yanping Hu

Blood (2021) 138 (Supplement 1): 1121.

https://doi.org/10.1182/blood-2021-145759

Published: 2021

Journal Articles

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

David C. Dale, Steven P. Treon, David F. McDermott, Diego Cadavid, Xia Luo, Varun Garg, Weihua Tang, Honghua Jiang, Kelly Chen, Arthur G. Taveras, Ashish Bhandari, Jean Donadieu

Blood (2021) 138 (Supplement 1): 2186.

https://doi.org/10.1182/blood-2021-152990

Published: 2021

Journal Articles

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Blood (2021) 138 (Supplement 1): 4310.

https://doi.org/10.1182/blood-2021-153346

Published: 2021

Journal Articles

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

David C. Dale, Frank Firkin, Audrey Anna Bolyard, Merideth Kelley, Vahagn Makaryan, Kenneth J. Gorelick, Tarek Ebrahim, Varun Garg, Weihua Tang, Honghua Jiang, Renato Skerlj, Sarah Beaussant Cohen

Blood (2020) 136 (26): 2994–3003.

https://doi.org/10.1182/blood.2020007197

Published: 2020

Includes: Supplemental data

NARROW

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

Email alerts

ASH Publications

American Society of Hematology

A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome

Mavorixafor, an Oral CXCR4 Antagonist, for Treatment of Patients with WHIM Syndrome: Results from the Long-Term Extension of the Open-Label Phase 2 Study

Oral Administration of Mavorixafor, a CXCR4 Antagonist, Increases Peripheral White Blood Cell Counts across Different Disease States

Global Phase 3, Randomized, Placebo-Controlled Trial with Open-Label Extension Evaluating the Oral CXCR4 Antagonist Mavorixafor in Patients with WHIM Syndrome (4WHIM): Trial Design and Enrollment

Results of a phase 2 trial of an oral CXCR4 antagonist, mavorixafor, for treatment of WHIM syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only